Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)

This study has been completed.
Beth Israel Deaconess Medical Center
Eli Lilly and Company
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Jorg Dietrich, M.D., Ph.D., Massachusetts General Hospital Identifier:
First received: June 5, 2009
Last updated: September 21, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2015
  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)